Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 30 2023 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2023
Commission File Number: 001-40858
XORTX Therapeutics Inc.
3710 – 33rd Street
NW, Calgary, Alberta, T2L 2M1
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
XORTX THERAPEUTICS INC. |
|
|
|
(Registrant) |
|
|
|
|
|
|
Date: |
June 29, 2023 |
By: |
/s/ Allen Davidoff |
|
|
|
Name: |
Allen Davidoff |
|
|
|
Title: |
Chief Executive Officer
|
|
EXHIBIT INDEX
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024